DecNef for AVH in Schizophrenia
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorNew York State Psychiatric Institute
About this trial
The purpose of this study is to learn whether a research neurofeedback training approach done during MRI scans may help reduce hallucinations such as the experience of hearing voices persistent despite treatment.
Eligibility criteria
Qualifiers
Individuals aged 18 to 55, inclusive at screen
Capable of understanding the study procedures and willing and able to provide informed consent
Diagnosed with schizophrenia or schizoaffective disorder
Taking an antipsychotic medication at a stable dose for at least 4 weeks. All oral and depot antipsychotics are allowable.
Disqualifiers
Diagnosis of moderate or severe substance use disorder (excluding nicotine) within the previous 90 days
Positive toxicology screen for any substances of abuse
Participation in study of investigational medication/device within the past 4 weeks
Pregnant persons. Persons of child-bearing potential must have a negative urine β-hCG pregnancy test at Visit 1 and Visit 1a (if applicable)
Trial design
Treatments tested in this trial
- Decoded Neurofeedback
Treatment groups
51 Participants
are divided into 2 treatment groupsSponsors and collaborators
New York State Psychiatric Institute
Lead sponsor
Columbia University
Collaborator
Source ClinicalTrials.gov